Akin I, Nienaber CA. Is there evidence for statins in the treatment of aortic valve stenosis? World J Cardiol 2017; 9(8): 667-672 [PMID: 28932355 DOI: 10.4330/wjc.v9.i8.667]
Corresponding Author of This Article
Dr. Ibrahim Akin, Professor, Medical Faculty Mannheim, University Heidelberg, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany. ibrahim.akin@umm.de
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Aug 26, 2017; 9(8): 667-672 Published online Aug 26, 2017. doi: 10.4330/wjc.v9.i8.667
Is there evidence for statins in the treatment of aortic valve stenosis?
Ibrahim Akin, Christoph A Nienaber
Ibrahim Akin, Medical Faculty Mannheim, University Heidelberg, 68167 Mannheim, Germany
Christoph A Nienaber, Royal Brompton Hospital and Harefield Trust, London SW3 6NP, United Kingdom
Author contributions: All the authors contributed to this manuscript.
Conflict-of-interest statement: No conflict of interest for all authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Ibrahim Akin, Professor, Medical Faculty Mannheim, University Heidelberg, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany. ibrahim.akin@umm.de
Telephone: +49-621-3835229 Fax: +49-621-3832012
Received: December 31, 2016 Peer-review started: January 7, 2017 First decision: February 17, 2017 Revised: February 21, 2017 Accepted: June 6, 2017 Article in press: June 8, 2017 Published online: August 26, 2017 Processing time: 236 Days and 1.6 Hours
Abstract
Research revealed that the pathogenesis of aortic stenosis (AS) not merely comprises of a mechanical wear and tear process yet that active biological processes, similar to those of coronary artery disease are involved, a promising role for statins in disease-modifying therapy was suggested. However, recently, many prospective studies could not observe decreased progression nor regression of the disease. Here, we review the current knowledge on the pathomechanisms of AS and its similarities and differences with atherosclerosis. Moreover, we discuss whether there is still a place for statins in the treatment of particular AS patient subgroups.
Core tip: Aortic stenosis is a age-dependent and growing disease. As there are several similarities with atherosclerotic disease of other regions there are growing research on underlying pathopyhsiology. The treatment benefit of classic atherosclerosis treatment is evaluated in case of aortic valve stenosis.
